EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance

Martina Bortolot, Sara Torresan iD, Elisa De Carlo, Elisa Bertoli iD, Brigida Stanzione iD, Alessandro Del Conte iD, Michele Spina, Alessandra Bearz iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252312972 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Martina Bortolot und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins B-raf, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although rare in non-small cell lung cancer (NSCLC), BRAF mutations present considerable therapeutic challenges. While the use of BRAF and MEK inhibitor combinations has significantly improved survival outcomes in patients with BRAF V600E mutations, no targeted therapies are currently available for class II and III mutations, leaving the optimal treatment strategy and prognosis for these patients uncertain. Additionally, despite immunotherapy typically showing limited benefit in patients with other activating genomic alterations, it appears to deliver comparable efficacy in BRAF-mutated NSCLC, emerging as a potentially viable treatment option, particularly in patients with a history of smoking. However, resistance to BRAF pathway inhibitors is inevitable, leading to disease progression, and a well-defined strategy to overcome these resistance mechanisms is lacking. This review aims to explore the critical challenges in the management of BRAF-mutated NSCLC, providing a comprehensive summary of the current evidence and highlighting ongoing clinical trials that aim to address these critical gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProto-Oncogene Proteins B-rafLung NeoplasmsMutationDrug Resistance, NeoplasmImmunotherapyHumansProtein Kinase Inhibitors

Stichwörter der Autor:innen

BRAF non-v600NSCLCimmunotherapyresistant mechanisms

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
  • Department of Medicine (DME), University of Udine, 33100 Udine, Italy.

ORCID-Profile: Sara Torresan, Elisa Bertoli, Brigida Stanzione, Alessandro Del Conte, Alessandra Bearz

Förderung

  • Italian Ministry of Health

Zitieren

APA

Bortolot, M., Torresan, S., De Carlo, E., Bertoli, E., Stanzione, B., Del Conte, A., Spina, M., & Bearz, A. (2024). Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312972

Vancouver

Bortolot M, Torresan S, De Carlo E, Bertoli E, Stanzione B, Del Conte A, et al. Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312972

BibTeX
@article{Bortolot2024,
  author = {Bortolot, Martina and Torresan, Sara and De Carlo, Elisa and Bertoli, Elisa and Stanzione, Brigida and Del Conte, Alessandro and Spina, Michele and Bearz, Alessandra},
  title = {Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252312972}
}
Kostenlos starten →